Amgen panitumumab BLA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen and Abgenix complete a rolling BLA submission for the epidermal growth factor inhibitor panitumumab to treat third-line metastatic colorectal cancer, the firms announce March 30. If granted a requested priority review, Amgen could see approval by September. Amgen presented data from the 463-patient pivotal trial supporting the BLA at the April 3 American Association for Cancer Research meeting in Washington, D.C. Amgen completed its $2.2. bil. acquisition of Abgenix on March 30; the deal was first announced in December (1Pharmaceutical Approvals Monthly January 2005, p. 42)...
You may also be interested in...
Licensing In Brief
Pfizer ups ante on Exubera approval with full license: Pfizer's decision to acquire Sanofi-Aventis' marketing rights to Exubera suggests the company is confident that the inhaled insulin product will receive FDA approval. Exubera's user fee date is Jan. 27, following a three-month extension resulting from an FDA request for additional technical chemistry data. Pfizer announced Jan. 12 that it will acquire worldwide rights for the development, production and commercialization of Exubera for $1.3 bil. - building on the firms' previous co-development alliance. The deal follows a judge's ruling that Sanofi's purchase of Aventis constituted a change-in-control under Pfizer and Aventis' 1998 agreement for Exubera. The NDA was submitted in March (1Pharmaceutical Approvals Monthly March 2005, p. 12)...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.